Search

Your search keyword '"Rodino, Stefano"' showing total 35 results
Start Over Author "Rodino, Stefano"
35 results on '"Rodino, Stefano"'

1. Examples of a Learning-By-Doing Approach for Bachelor and Master Students Approaching Robot Design

Author

Curcio, Elio Matteo, Lago, Francesco, Rodino, Stefano, Carbone, Giuseppe, Ceccarelli, Marco, Series Editor, Agrawal, Sunil K., Advisory Editor, Corves, Burkhard, Advisory Editor, Glazunov, Victor, Advisory Editor, Hernández, Alfonso, Advisory Editor, Huang, Tian, Advisory Editor, Jauregui Correa, Juan Carlos, Advisory Editor, Takeda, Yukio, Advisory Editor, and Jauregui-Correa, Juan Carlos, editor

Published
2024
Full Text
View/download PDF

4. An Automatic Measurement System for Shape Memory Alloys’ Wire Resistivity Characterization

Author

Siciliano, Marco, Lamonaca, Francesco, Carnì, Domenico Luca, Rodinò, Stefano, Curcio, Elio Matteo, Carbone, Giuseppe, Mundo, Domenico, Maletta, Carmine, Ceccarelli, Marco, Series Editor, Agrawal, Sunil K., Advisory Editor, Corves, Burkhard, Advisory Editor, Glazunov, Victor, Advisory Editor, Hernández, Alfonso, Advisory Editor, Huang, Tian, Advisory Editor, Jauregui Correa, Juan Carlos, Advisory Editor, Takeda, Yukio, Advisory Editor, Petuya, Victor, editor, Quaglia, Giuseppe, editor, Parikyan, Tigran, editor, and Carbone, Giuseppe, editor

Published
2023
Full Text
View/download PDF

7. Modelling and Simulation of ADIUTOR Upper Limb Rehabilitation Robot

Author

Curcio, Elio M., Quacquarelli, Mariagrazia, Cariven, Léa L. H. I., Pitti, Estelle M. C., De Momi, Elena, Lago, Francesco, Rodino’, Stefano, Carbone, Giuseppe, Ceccarelli, Marco, Series Editor, Agrawal, Sunil K., Advisory Editor, Corves, Burkhard, Advisory Editor, Glazunov, Victor, Advisory Editor, Hernández, Alfonso, Advisory Editor, Huang, Tian, Advisory Editor, Jauregui Correa, Juan Carlos, Advisory Editor, Takeda, Yukio, Advisory Editor, Niola, Vincenzo, editor, Gasparetto, Alessandro, editor, Quaglia, Giuseppe, editor, and Carbone, Giuseppe, editor

Published
2022
Full Text
View/download PDF

9. Changes in digestive cancer diagnosis during the SARS-CoV-2 pandemic in Italy: A nationwide survey

Author

Massironi, Sara, Bianco, Maria Antonia, Germanà, Bastianello, Rodinò, Stefano, Anderloni, Andrea, Mussetto, Alessandro, Nipote, Bruno, Russo, Salvatore, Manta, Raffaele, Lauri, Adriano, Occhipinti, Vincenzo, Marco, Marco Di, Giovannone, Maurizio, Binda, Cecilia, Sbrancia, Monica, Paolo, Maria Carla Di, de’-Angelis, Gian Luigi, Fiori, Giancarla, Dal-Fante, Marco, Caro, Giuseppe de, Usai-Satta, Paolo, Cesarini, Monica, Piras, Enrico, Stasi, Elisa, Serio, Giovanni, Montalbano, Luigi Maria, Mirante, Vincenzo Giorgio, Burattini, Osvaldo, Attardo, Simona, Bargiggia, Stefano, Dinca, Manuele, Missale, Guido, Alvisi, Costanza, Broglia, Francesco, Ferraris, Luca, Conti-Bellocchi, Maria Cristina, Luigiano, Carmelo, Pallio, Socrate, Brunacci, Matteo, Manfrini, Carlo, Bozzi, Rosamaria, Checchin, Davide, Togliani, Thomas, D'errico, Antonietta, Bazzoli, Franco, La Bianca, Orazio, Berretti, Debora, Alvaro, Domenico, Buscarini, Elisabetta, Benedetti, Antonio, Monica, Fabio, Pasquale, Luigi, Buttitta, Francesco, Cameletti, Michela, Ferrari, Clarissa, and Ricciardiello, Luigi

Published
2021
Full Text
View/download PDF

11. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers

Author

Tursi, Antonio, Mocci, Giammarco, Faggiani, Roberto, Allegretta, Leonardo, Valle, Nicola Della, Medici, Antonio de, Forti, Giacomo, Franceschi, Marilisa, Ferronato, Antonio, Gallina, Sara, Grasso, Giuseppina, Larussa, Tiziana, Luzza, Francesco, Lorenzetti, Roberto, Penna, Antonio, Rodino', Stefano, Sebkova, Ladislava, Lauria, Angelo, Piergallini, Simona, Pranzo, Giuseppe, Scorza, Stefano, Zampaletta, Costantino, Picchio, Marcello, and Elisei, Walter

Published
2019
Full Text
View/download PDF

12. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study

Author

Mocci, Giammarco, Tursi, Antonio, Maconi, Giovanni, Cataletti, Giovanni, Mantia, Beatrice, Serio, Mariaelena, Scarcelli, Antonella, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Pranzo, Giuseppe, Luppino, Ileana, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Ferronato, Antonio, Perini, Barbara, Savarino, Edoardo, Onidi, Francesca Maria, Binaghi, Laura, Usai Satta, Paolo, Schiavoni, Elisa, Napolitano, Daniele, Scaldaferri, Franco, Pugliese, Daniela, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Rodino, Stefano, Sebkova, Ladislava, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Gaiani, Federica, De Angelis, Gianluigi, Kayali, Stefano, Fanigliulo, Libera, Lorenzetti, Roberto, Allegretta, Leonardo, Scorza, Stefano, Cuomo, Antonio, Donnarumma, Laura, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Antonelli, Elisabetta, Bassotti, Gabrio, Iannelli, Chiara, Luzza, Francesco, Aragona, Giovanni, Perazzo, Patrizia, Lauria, Angelo, Piergallini, Simona, Colucci, Raffaele, Bianco, Maria Antonia, Meucci, Costantino, Giorgetti, Gianmarco, Clemente, Valeria, Fiorella, Serafina, Penna, Antonio, De Medici, Antonio, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Mocci, Giammarco, Tursi, Antonio, Maconi, Giovanni, Cataletti, Giovanni, Mantia, Beatrice, Serio, Mariaelena, Scarcelli, Antonella, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Pranzo, Giuseppe, Luppino, Ileana, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Ferronato, Antonio, Perini, Barbara, Savarino, Edoardo, Onidi, Francesca Maria, Binaghi, Laura, Usai Satta, Paolo, Schiavoni, Elisa, Napolitano, Daniele, Scaldaferri, Franco, Pugliese, Daniela, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Rodino, Stefano, Sebkova, Ladislava, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Gaiani, Federica, De Angelis, Gianluigi, Kayali, Stefano, Fanigliulo, Libera, Lorenzetti, Roberto, Allegretta, Leonardo, Scorza, Stefano, Cuomo, Antonio, Donnarumma, Laura, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Antonelli, Elisabetta, Bassotti, Gabrio, Iannelli, Chiara, Luzza, Francesco, Aragona, Giovanni, Perazzo, Patrizia, Lauria, Angelo, Piergallini, Simona, Colucci, Raffaele, Bianco, Maria Antonia, Meucci, Costantino, Giorgetti, Gianmarco, Clemente, Valeria, Fiorella, Serafina, Penna, Antonio, De Medici, Antonio, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)

Abstract

BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Research design and methods Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6(th) month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6(th) month of treatment (p=0.001) and being naive to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).ConclusionWe found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.

Published
2023

13. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study

Author

Tursi, Antonio, Mocci, Giammarco, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Cuomo, Antonio, Della Valle, Nicola, Ferronato, Antonio, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Pica, Roberta, Pranzo, Giuseppe, Rodino', Stefano, Scarcelli, Antonella, Zampaletta, Costantino, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De' Angelis, Gianluigi, Donnarumma, Laura, Faggiani, Roberto, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Picchio, Marcello, Sacco, Rodolfo, Sebkova, Ladislava, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Scaldaferri, Franco, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Elisei, Walter, Maconi, Giovanni, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Mocci, Giammarco, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Cuomo, Antonio, Della Valle, Nicola, Ferronato, Antonio, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Pica, Roberta, Pranzo, Giuseppe, Rodino', Stefano, Scarcelli, Antonella, Zampaletta, Costantino, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De' Angelis, Gianluigi, Donnarumma, Laura, Faggiani, Roberto, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Picchio, Marcello, Sacco, Rodolfo, Sebkova, Ladislava, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Scaldaferri, Franco, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Elisei, Walter, Maconi, Giovanni, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), and Papa, Alfredo (ORCID:0000-0002-4186-7298)

Abstract

Background Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the originator. However, comparative data on the efficacy and safety of the various ADA biosimilars remains scarce. We compare the efficacy and safety of ADA biosimilars SB5, APB501, GP2017, and MSB11022 in treating IBD outpatients in a real-life Italian setting. Methods A retrospective analysis was performed on consecutive IBD outpatients with complete clinical, laboratory, and endoscopic data. Clinical activity was measured using the Mayo score in ulcerative colitis (UC) and the Harvey-Bradshaw Index in Crohn's disease (CD). The primary endpoints were the following: (1) induction of remission in patients new to biologics and patients new to ADA but previously exposed to other anti-tumor necrosis factor agents or other biologics; (2) maintenance of remission in patients switched from the ADA originator to an ADA biosimilar; and (3) safety of various biosimilars. Results A total of 533 patients were enrolled according to the inclusion criteria: 162 patients with UC and 371 patients with CD. Clinical remission was obtained in 79.6% of patients new to biologics and 59.2% of patients new to ADA but not to other biologics; clinical remission was maintained in 81.0% of patients switched from the originator, and adverse events were recorded in 6.7% of patients. There was no significant difference between the 4 ADA biosimilars for each predetermined endpoint. Conclusions Adalimumab biosimilars are effective and safe in IBD treatment, both in new patients and in patients switched from the ADA originator. No difference in efficacy and safety was found between ADA biosimilars.Lay Summary We treated 533 IBD patients with adalimumab (ADA) biosimilars SB5, APB501, GP2017, and MSB11022. No differences between these 4 ADA biosimilars were found for reaching remission in naive p

Published
2023

14. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study

Author

Mocci, Giammarco, primary, Tursi, Antonio, additional, Maconi, Giovanni, additional, Cataletti, Giovanni, additional, Mantia, Beatrice, additional, Serio, Mariaelena, additional, Scarcelli, Antonella, additional, Pagnini, Cristiano, additional, Graziani, Maria Giovanna, additional, Di Paolo, Maria Carla, additional, Pranzo, Giuseppe, additional, Luppino, Ileana, additional, Paese, Pietro, additional, Elisei, Walter, additional, Monterubbianesi, Rita, additional, Faggiani, Roberto, additional, Ferronato, Antonio, additional, Perini, Barbara, additional, Savarino, Edoardo, additional, Onidi, Francesca Maria, additional, Binaghi, Laura, additional, Usai Satta, Paolo, additional, Schiavoni, Elisa, additional, Napolitano, Daniele, additional, Scaldaferri, Franco, additional, Pugliese, Daniela, additional, Pica, Roberta, additional, Cocco, Andrea, additional, Zippi, Maddalena, additional, Rodino, Stefano, additional, Sebkova, Ladislava, additional, Rocco, Giulia, additional, Sacchi, Carlotta, additional, Zampaletta, Costantino, additional, Gaiani, Federica, additional, De Angelis, Gianluigi, additional, Kayali, Stefano, additional, Fanigliulo, Libera, additional, Lorenzetti, Roberto, additional, Allegretta, Leonardo, additional, Scorza, Stefano, additional, Cuomo, Antonio, additional, Donnarumma, Laura, additional, Della Valle, Nicola, additional, Sacco, Rodolfo, additional, Forti, Giacomo, additional, Antonelli, Elisabetta, additional, Bassotti, Gabrio, additional, Iannelli, Chiara, additional, Luzza, Francesco, additional, Aragona, Giovanni, additional, Perazzo, Patrizia, additional, Lauria, Angelo, additional, Piergallini, Simona, additional, Colucci, Raffaele, additional, Bianco, Maria Antonia, additional, Meucci, Costantino, additional, Giorgetti, Gianmarco, additional, Clemente, Valeria, additional, Fiorella, Serafina, additional, Penna, Antonio, additional, De Medici, Antonio, additional, Picchio, Marcello, additional, and Papa, Alfredo, additional

Published
2023
Full Text
View/download PDF

15. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy

Author

Tursi, Antonio, primary, Mocci, Giammarco, primary, Cuomo, Antonio, primary, Ferronato, Antonio, primary, Elisei, Walter, primary, Picchio, Marcello, primary, Maconi, Giovanni, primary, Scaldaferri, Franco, primary, Papa, Alfredo, primary, Italian group for switch of biologics, -, primary, Allegretta, Leonardo, primary, Aragona, Giovanni, primary, Bianco, Maria Antonia, primary, Colucci, Raffaele, primary, Della Valle, Nicola, primary, Faggiani, Roberto, primary, Forti, Giacomo, primary, Gaiani, Federica, primary, Giorgetti, GianMarco, primary, Graziani, Maria Giovanna, primary, Lofano, Katia, primary, Lorenzetti, Roberto, primary, Larussa, Tiziana, primary, Penna, Antonio, primary, Bassotti, Gabrio, primary, Cazzato, Alessia Immacolata, primary, Chiri, Stefania, primary, Clemente, Valeria, primary, Cocco, Andrea, primary, De’ Angelis, Gianluigi, primary, Donnarumma, Laura, primary, Graziosi, Camilla, primary, Le Grazie, Marco, primary, Luzza, Francesco, primary, Meucci, Costantino, primary, Monterubbianesi, Rita, primary, Pagnini, Cristiano, primary, Perazzo, Patrizia, primary, Pica, Roberta, primary, Pranzo, Giuseppe, primary, Rodino’, Stefano, primary, Sacco, Rodolfo, primary, Sebkova, Ladislava, primary, Scarcelli, Antonella, primary, Serio, Mariaelena, primary, Napolitano, Daniele, primary, Pugliese, Daniela, primary, Schiavoni, Elisa, primary, Turchini, Laura, primary, Armuzzi, Alessandro, primary, and Zampaletta, Costantino, primary

Published
2022
Full Text
View/download PDF

16. Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers

Author

Tursi, Antonio, Elisei, Walter, Faggiani, Roberto, Allegretta, Leonardo, Valle, Nicola Della, Forti, Giacomo, Franceschi, Marilisa, Ferronato, Antonio, Gallina, Sara, Larussa, Tiziana, Luzza, Francesco, Lorenzetti, Roberto, Mocci, Giammarco, Penna, Antonio, Rodino’, Stefano, Sebkova, Ladislava, de Medici, Antonio, Pranzo, Giuseppe, Ricciardelli, Cristina, Grasso, Giuseppina, Scorza, Stefano, Zampaletta, Costantino, and Picchio, Marcello

Published
2018
Full Text
View/download PDF

17. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy

Author

Tursi, Antonio, Mocci, Giammarco, Cuomo, Antonio, Ferronato, Antonio, Elisei, Walter, Picchio, Marcello, Maconi, Giovanni, Scaldaferri, Franco, Papa, Alfredo, Italian group for switch of biologics,, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Della Valle, Nicola, Faggiani, Roberto, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De’ Angelis, Gianluigi, Donnarumma, Laura, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Pica, Roberta, Pranzo, Giuseppe, Rodino’, Stefano, Sacco, Rodolfo, Sebkova, Ladislava, Scarcelli, Antonella, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Zampaletta, Costantino, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Mocci, Giammarco, Cuomo, Antonio, Ferronato, Antonio, Elisei, Walter, Picchio, Marcello, Maconi, Giovanni, Scaldaferri, Franco, Papa, Alfredo, Italian group for switch of biologics,, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Della Valle, Nicola, Faggiani, Roberto, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De’ Angelis, Gianluigi, Donnarumma, Laura, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Pica, Roberta, Pranzo, Giuseppe, Rodino’, Stefano, Sacco, Rodolfo, Sebkova, Ladislava, Scarcelli, Antonella, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Zampaletta, Costantino, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)

Abstract

Background & Aims: Adalimumab (ADA) biosimilars have been included into the therapeutic armamentarium of inflammatory bowel disease (IBD); however, comparative data on the efficacy and safety of the different ADA biosimilars after replacing the ADA originator for a non-medical reason remains scarce. We aimed to compare in a real-life setting the efficacy and safety of four ADA biosimilars SB5, APB501, GP2017, and MSB11022 in IBD patients after replacing the originator for a non-medical reason.Methods: A multicenter retrospective study was performed on consecutive IBD patients, analyzing clinical, laboratory, and endoscopic data. The primary endpoints of the study were maintenance of clinical remission and safety of the different biosimilars.Results: 153 patients were enrolled, 26 with UC and 127 with CD. Clinical remission was maintained in 124 out of 153 (81%) patients after a median (IQR) follow-up of 12 (6-24) months, without any significant difference between the four ADA biosimilars. ADA biosimilars dosage was optimized in five patients (3.3%). Loss of remission was significantly higher in UC patients (10/26 patients, 38.5%) than in CD patients (19/127 patients, 14.9%, p<0.025). Adverse events occurred in 12 (7.9%) patients; the large majority were mild.Conclusions: No difference in efficacy and safety was found between ADA biosimilars when used to replace the ADA originator for a non-medical reason. However, in UC patients the replacement of ADA originator for this reason should be carefully assessed.

Published
2022

18. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study

Author

Tursi, Antonio, primary, Mocci, Giammarco, additional, Allegretta, Leonardo, additional, Aragona, Giovanni, additional, Bianco, Maria Antonia, additional, Colucci, Raffaele, additional, Cuomo, Antonio, additional, Della Valle, Nicola, additional, Ferronato, Antonio, additional, Forti, Giacomo, additional, Gaiani, Federica, additional, Giorgetti, GianMarco, additional, Graziani, Maria Giovanna, additional, Lofano, Katia, additional, Lorenzetti, Roberto, additional, Larussa, Tiziana, additional, Penna, Antonio, additional, Pica, Roberta, additional, Pranzo, Giuseppe, additional, Rodino’, Stefano, additional, Scarcelli, Antonella, additional, Zampaletta, Costantino, additional, Bassotti, Gabrio, additional, Cazzato, Alessia Immacolata, additional, Chiri, Stefania, additional, Clemente, Valeria, additional, Cocco, Andrea, additional, de’ Angelis, Gianluigi, additional, Donnarumma, Laura, additional, Faggiani, Roberto, additional, Graziosi, Camilla, additional, Le Grazie, Marco, additional, Luzza, Francesco, additional, Meucci, Costantino, additional, Monterubbianesi, Rita, additional, Pagnini, Cristiano, additional, Perazzo, Patrizia, additional, Picchio, Marcello, additional, Sacco, Rodolfo, additional, Sebkova, Ladislava, additional, Serio, Mariaelena, additional, Napolitano, Daniele, additional, Pugliese, Daniela, additional, Scaldaferri, Franco, additional, Schiavoni, Elisa, additional, Turchini, Laura, additional, Armuzzi, Alessandro, additional, Elisei, Walter, additional, Maconi, Giovanni, additional, and Papa, Alfredo, additional

Published
2022
Full Text
View/download PDF

19. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients

Author

Tursi, Antonio, primary, Mocci, Giammarco, additional, Lorenzetti, Roberto, additional, Allegretta, Leonardo, additional, Brandimarte, Giovanni, additional, Cassieri, Claudio, additional, Colucci, Raffaele, additional, De Medici, Antonio, additional, Faggiani, Roberto, additional, Ferronato, Antonio, additional, Fiorella, Serafina, additional, Forti, Giacomo, additional, Franceschi, Marilisa, additional, Gallina, Sara, additional, Giorgetti, GianMarco, additional, Grasso, Giuseppina, additional, Larussa, Tiziana, additional, Luzza, Francesco, additional, Penna, Antonio, additional, Pica, Roberta, additional, Piergallini, Simona, additional, Porciello, Sarah, additional, Pranzo, Giuseppe, additional, Rodino’, Stefano, additional, Scorza, Stefano, additional, Sebkova, Ladislava, additional, Zampaletta, Costantino, additional, Elisei, Walter, additional, and Picchio, Marcello, additional

Published
2021
Full Text
View/download PDF

20. Mo1867 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Author

Pugliese, Daniela, primary, Privitera, Giuseppe, additional, Crispino, Federica, additional, Mezzina, Nicolò, additional, Pellegrini, Lucienne, additional, Laterza, Lucrezia, additional, Viola, Anna, additional, Soru, Pietro, additional, Scrivo, Barbara, additional, Barberio, Brigida, additional, Ricci, Chiara, additional, pluchino, dario, additional, Scribano, Maria Lia, additional, Bertani, Lorenzo, additional, Sablich, Renato, additional, Pastorelli, Luca, additional, Manguso, Francesco, additional, Variola, Angela, additional, Di Sario, Antonio, additional, Grossi, Laurino, additional, Ribaldone, Davide Giuseppe, additional, Biscaglia, Giuseppe, additional, Buda, Andrea, additional, Balestrieri, Paola, additional, Mocci, Giammarco, additional, Viscido, Angelo, additional, Di Paolo, Maria Carla, additional, Onali, Sara, additional, Rodino', Stefano, additional, Coletta, Marina, additional, Principi, Mariabeatrice, additional, Miranda, Agnese, additional, Amato, Arnaldo, additional, Bezzio, Cristina, additional, Petruzzellis, Carlo, additional, Mazzuoli, Silvia, additional, Festa, Stefano, additional, Sartini, Alessandro, additional, Fanigliulo, Libera, additional, Gallina, Sara, additional, Bodini, Giorgia, additional, Guidi, Luisa, additional, Savarino, Edoardo, additional, Cappello, Maria, additional, Caprioli, Flavio, additional, Fries, Walter, additional, Scaldaferri, Franco, additional, Castiglione, Fabiana, additional, Massari, Alessandro, additional, Orlando, Ambrogio, additional, and Armuzzi, Alessandro, additional

Published
2020
Full Text
View/download PDF

21. Sa1825 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT

Author

Pugliese, Daniela, primary, Privitera, Giuseppe, additional, Crispino, Federica, additional, Mezzina, Nicolò, additional, Pellegrini, Lucienne, additional, Laterza, Lucrezia, additional, Viola, Anna, additional, Soru, Pietro, additional, Scrivo, Barbara, additional, Barberio, Brigida, additional, Ricci, Chiara, additional, pluchino, dario, additional, Scribano, Maria Lia, additional, Bertani, Lorenzo, additional, Sablich, Renato, additional, Pastorelli, Luca, additional, Manguso, Francesco, additional, Variola, Angela, additional, Di Sario, Antonio, additional, Grossi, Laurino, additional, Ribaldone, Davide Giuseppe, additional, Biscaglia, Giuseppe, additional, Buda, Andrea, additional, Balestrieri, Paola, additional, Mocci, Giammarco, additional, Viscido, Angelo, additional, Di Paolo, Maria Carla, additional, Onali, Sara, additional, Rodino', Stefano, additional, Coletta, Marina, additional, Principi, Mariabeatrice, additional, Miranda, Agnese, additional, Amato, Arnaldo, additional, Bezzio, Cristina, additional, Petruzzellis, Carlo, additional, Mazzuoli, Silvia, additional, Festa, Stefano, additional, Sartini, Alessandro, additional, Fanigliulo, Libera, additional, Gallina, Sara, additional, Bodini, Giorgia, additional, Guidi, Luisa, additional, Savarino, Edoardo, additional, Cappello, Maria, additional, Caprioli, Flavio, additional, Fries, Walter, additional, Scaldaferri, Franco, additional, Castiglione, Fabiana, additional, Massari, Alessandro, additional, Orlando, Ambrogio, additional, and Armuzzi, Alessandro, additional

Published
2020
Full Text
View/download PDF

22. Tu1237 - Epidemiology of Diverticular Disease of the Colon: A Preliminary Analysis from the International “Dica” Prospective Study

Author

Tursi, Antonio, primary, Brandimarte, Giovanni, additional, Di Mario, Francesco, additional, Elisei, Walter, additional, Picchio, Marcello, additional, Annunziata, Maria Laura, additional, Bafutto, Mauro, additional, Baldi, Fabio, additional, Danese, Silvio, additional, Dumitrascu, Dan Lucian, additional, Escalante, Ricardo, additional, Faggiani, Roberto, additional, Forti, Giacomo, additional, Franceschi, Marilisa, additional, Graziani, Maria G., additional, Lammert, Frank, additional, Latella, Giovanni, additional, Murphy, Maria M., additional, Oliveira, Lucia C., additional, Oliveira, Enio C., additional, Papagrigoriadis, Savvas, additional, Penna, Antonio, additional, Pietrzak, Anna, additional, Poskus, Tomas, additional, Reichert, Matthias, additional, Rodino', Stefano, additional, Regula, Jaroslaw, additional, Vassallo, Roberto, additional, and Walker, Marjorie M., additional

Published
2018
Full Text
View/download PDF

23. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.

Author

Tursi, Antonio, Mocci, Giammarco, Faggiani, Roberto, Allegretta, Leonardo, Valle, Nicola Della, Forti, Giacomo, Franceschi, Marilisa, Ferronato, Antonio, Gallina, Sara, Larussa, Tiziana, Luzza, Francesco, Lorenzetti, Roberto, Penna, Antonio, Rodino, Stefano, Sebkova, Ladislava, Lauria, Angelo, Piergallini, Simona, Pranzo, Giuseppe, Ricciardelli, Cristina, and Zampaletta, Costantino

Subjects
INFLAMMATORY bowel diseases, CROHN'S disease, ULCERATIVE colitis, GASTROENTEROLOGY, RESTORATIVE proctocolectomy, INFLIXIMAB, SCIENTIFIC observation
Abstract

Background The purpose of this study was to assess the efficacy and safety of biosimilar infliximab (IFX) CT-P13 in treating outpatients with inflammatory bowel disease (IBD) in Italian primary gastroenterology centers. Methods Consecutive IBD outpatients who completed the induction treatment were evaluated retrospectively. Clinical activity was scored according to the Mayo score for ulcerative colitis (UC) and to the Harvey-Bradshaw Index (HBI) for Crohn's disease (CD). The primary endpoint was the achievement of clinical remission (Mayo score =2 in UC and HBI =5 in CD). Secondary endpoints were clinical response to treatment, achievement of mucosal healing, and safety. Results One hundred forty-one patients (96 UC and 45 CD) were enrolled. Previous treatment with anti-tumor necrosis factor (TNF)á had been provided to 26% of UC patients and 28.9% of CD patients. Remission was achieved in 57.3% UC patients and in 75.6% CD patients during a median (interquartile range) follow up of 24 (6-24) months. Clinical response and mucosal healing were achieved in 87.5% and 75.0% of UC patients and in 84.4% and 84.2% of CD patients, respectively. By both univariate and multivariate analysis, age >40 years, presence of comorbidities, and naivety to anti-TNFá were significantly related to remission. Only one (0.7%) adverse event was reported in the CD group. Surgery was performed in 2.1% of UC patients and 6.7% of CD patients. Switching from IFX originator to biosimilar did not influence the maintenance of the clinical remission. Conclusion This study confirmed the long-term efficacy and safety of CT-P13 therapy in IBD, in both naïve patients and those switching from IFX originator. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

25. 274 Mesalazine and/or Lactobacillus Casei in Maintaining Remission of Symptomatic Uncomplicated Diverticular Disease of the Colon: A Randomised, Double-Blind, Placebo-Controlled Study

Author

Tursi, Antonio, primary, Brandimarte, Giovanni, additional, Elisei, Walter, additional, Giorgetti, GianMarco, additional, Forti, Giacomo, additional, Rodino, Stefano, additional, Sacca, Natale, additional, D'Amico, Teresa, additional, Portincasa, Piero, additional, Lecca, Piera Giuseppina, additional, Di Cesare, Luigi, additional, Picchio, Marcello, additional, and Danese, Silvio, additional

Published
2013
Full Text
View/download PDF

30. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study

Author

Tursi, Antonio, primary, Brandimarte, Giovanni, additional, Papa, Alfredo, additional, Giglio, Andrea, additional, Elisei, Walter, additional, Giorgetti, Gian Marco, additional, Forti, Giacomo, additional, Morini, Sergio, additional, Hassan, Cesare, additional, Pistoia, Maria Antonietta, additional, Modeo, Maria Ester, additional, Rodino', Stefano, additional, D'Amico, Teresa, additional, Sebkova, Ladislava, additional, Sacca', Natale, additional, Di Giulio, Emilio, additional, Luzza, Francesco, additional, Imeneo, Maria, additional, Larussa, Tiziana, additional, Di Rosa, Salvatore, additional, Annese, Vito, additional, Danese, Silvio, additional, and Gasbarrini, Antonio, additional

Published
2010
Full Text
View/download PDF

31. What's Hot in the Red Journal This Month

Author

Tursi, Antonio, primary, Brandimarte, Giovanni, additional, Papa, Alfredo, additional, Giglio, Andrea, additional, Elisei, Walter, additional, Giorgetti, Gian Marco, additional, Forti, Giacomo, additional, Morini, Sergio, additional, Hassan, Cesare, additional, Pistoia, Maria Antonietta, additional, Modeo, Maria Ester, additional, Rodino', Stefano, additional, D'Amico, Teresa, additional, Sebkova, Ladislava, additional, Sacca', Natale, additional, Di Giulio, Emilio, additional, Luzza, Francesco, additional, Imeneo, Maria, additional, Larussa, Tiziana, additional, Di Rosa, Salvatore, additional, Annese, Vito, additional, Danese, Silvio, additional, and Gasbarrini, Antonio, additional

Published
2010
Full Text
View/download PDF

32. Bile and biliary lipid secretion in rats with hexachlorobenzene-induced porphyria. Effect of S-adenosyl-l-methionine administration

Author

Cuomo, Rosario, primary, Rodino, Stefano, additional, Rizzoh, Raffaella, additional, Simoni, Patrizia, additional, Roda, Enrico, additional, Cantoni, Lavinia, additional, Rizzardini, Milena, additional, De Rosa, Gaetano, additional, Le Grazie, Cristina, additional, Di Padova, Carlo, additional, and Budillon, Gabriele, additional

Published
1991
Full Text
View/download PDF

33. The 'DICA' endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists

Author

Antonio, Tursi, Giovanni, Brandimarte, Francesco di Mario, Gerardo, Nardone, Carmelo, Scarpignato, Picchio, Marcello, Walter, Elisei, Leonardo, Allegretta, Maria Laura Annunziata, Marco, Astegiano, Fabio, Baldi, Gabrio, Bassotti, Bianco, Maria Antonietta, Ginevra, Cambie, Erminio, Capezzuto, Caroli, Alessandro, Cassieri, Claudio, Antonio Salvatore Cicu, Enrico, Ciliberto, Raffaele, Colucci, Rita, Conigliaro, Alberto, Damiani, Patrizia De Colibus, Antonio De Medici, Giovanni De Pretis, Giuseppe Del Favero, Nicola Della Valle, Luigi Di Cesare, Roberto, Faggiani, Stefania, Febbraro, Luciano, Ferrini, Serafina, Fiorella, Giacomo, Forti, Marilisa, Franceschi, Andrea, Frunzio, Bastianello, Germana’, Gian Marco Giorgetti, Maurizio, Giovannone, Maria Giovanna Graziani, Maria Antonia Lai, Giovanni, Latella, Piera Giuseppina Lecca, Daniele, Lisi, Loris Riccardo Lopetuso, Giovanni, Maconi, Enzo Domenico Mandelli, Riccardo, Marmo, Attilio, Maurano, Lorella, Pallotta, Alfredo, Papa, Francesca, Parmeggiani, Penna, ANTONIO DOMENICO, Flavia, Pigo’, Pontone, Stefano, Giuseppe, Pranzo, Cristina, Ricciardelli, Giovanni Luca Rizzo, Stefano, Rodino’, Edoardo, Savarino, Giuseppe, Scaccianoce, Franco, Scaldaferri, Luigi, Schiffino, Chiara, Semeraro, Italo, Stroppa, Riccardo, Urgesi, Vassallo, Roberto, Alessandra, Violi, Costantino, Zampaletta, Maurizio, Zilli, Angelo, Zullo, Tursi, Antonio, Brandimarte, Giovanni, Carillo, MARIO FRANCESCO, Nardone, Gerardo, Scarpignato, Carmelo, Picchio, Marcello, Elisei, Walter, Allegretta, Leonardo, Annunziata, MARIA LAURA, Astegiano, Marco, Baldi, Fabio, Bassotti, Gabrio, Bianco, Maria Antonietta, Cambie, Ginevra, Capezzuto, Erminio, Caroli, Alessandro, Cassieri, Claudio, Cicu, Antonio Salvatore, Ciliberto, Enrico, Colucci, Raffaele, Conigliaro, Rita, Damiani, Alberto, De Colibus, Patrizia, De Medici, Antonio, De Pretis, Giovanni, Del Favero, Giuseppe, Valle, Nicola Della, Di Cesare, Luigi, Faggiani, Roberto, Febbraro, Stefania, Ferrini, Luciano, Fiorella, Serafina, Forti, Giacomo, Franceschi, Marilisa, Frunzio, Andrea, Germana’, Bastianello, Giorgetti, Gian Marco, Giovannone, Maurizio, Graziani, Maria Giovanna, Lai, Maria Antonia, Latella, Giovanni, Lecca, Piera Giuseppina, Lisi, Daniele, Lopetuso, Loris Riccardo, Maconi, Giovanni, Mandelli, Enzo Domenico, Marmo, Riccardo, Maurano, Attilio, Pallotta, Lorella, Papa, Alfredo, Parmeggiani, Francesca, Penna, Antonio, Pigo’, Flavia, Pontone, Stefano, Pranzo, Giuseppe, Ricciardelli, Cristina, Rizzo, Giovanni Luca, Rodino’, Stefano, Savarino, Edoardo, Scaccianoce, Giuseppe, Scaldaferri, Franco, Schiffino, Luigi, Semeraro, Chiara, Stroppa, Italo, Urgesi, Riccardo, Vassallo, Roberto, Violi, Alessandra, Zampaletta, Costantino, Zilli, Maurizio, and Zullo, Angelo

Subjects
medicine.medical_specialty, Scoring system, Colon, Settore MED/12 - GASTROENTEROLOGIA, agreement, colonoscopy, diverticular disease of the colon, endoscopic classification, Video Recording, Colonoscopy, Agreement, Diverticular disease of the colon, Endoscopic classification, Diverticulitis, Colonic, Diverticulosis, Colonic, Humans, Observer Variation, Predictive Value of Tests, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Terminology as Topic, Single item, Colonic, Internal medicine, medicine, Diverticulitis, Diverticulosis, medicine.diagnostic_test, business.industry, Gastroenterology, Expert group, Diverticular disease, Community setting, business, Kappa
Abstract

Background & Aim: An endoscopic classification of Diverticular Disease (DD), called DICA (Diverticular Inflammation and Complication Assessment) is currently available. It scores severity of the disease as DICA 1, DICA 2 and DICA 3. Our aim was to assess the agreement levels for this classification among an endoscopist community setting.Methods: A total of 66 endoscopists independently scored a set of DD endoscopic videos. The percentages of overall agreement on the DICA score and a free-marginal multirater kappa (κ) coefficient were reported as statistical measures of the inter-rater agreement.Results: The overall agreement levels were: 70.2% for DICA 1, 70.5% for DICA 2, 81.3% for DICA 3. The free marginal κ was: 0.553 for DICA 1, 0.558 for DICA 2, 0.719 for DICA 3. The agreement levels among the expert group were: 78.8% for DICA 1, 80.2% for DICA 2, 88.5% for DICA 3. The free marginal κ among the expert group were: 0.682 for DICA 1, 0.712 for DICA 2, 0.828 for DICA 3. The agreement of expert raters on the single item of the DICA classification was superior to the agreement of the overall group.Conclusions: The overall inter-rater agreement for DICA score in this study ranges from moderate to good, with a significant improvement in the expert subgroup of raters. Diverticular Inflammation and Complication Assessment is a simple and reproducible endoscopic scoring system.

Published
2019

34. Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study.

Author

Tursi A, Piovani D, Brandimarte G, Di Mario F, Elisei W, Picchio M, Figlioli G, Bassotti G, Allegretta L, Annunziata ML, Bafutto M, Bianco MA, Colucci R, Conigliaro R, Dumitrascu DL, Escalante R, Ferrini L, Forti G, Franceschi M, Graziani MG, Lammert F, Latella G, Lisi D, Maconi G, Compare D, Nardone G, Camara de Castro Oliveira L, Enio CO, Papagrigoriadis S, Pietrzak A, Pontone S, Stundiene I, Poškus T, Pranzo G, Reichert MC, Rodino S, Regula J, Scaccianoce G, Scaldaferri F, Vassallo R, Zampaletta C, Zullo A, Spaziani E, Bonovas S, Papa A, and Danese S

Abstract

Background/aims: Patients with diverticular disease (DD) frequently have abnormal bowel movements. However, it is unknown whether the entity of these alterations is associated with the severity of DD. We aimed to assess bowel habits and their relationship with the severity of DD according to Diverticular Inflammation and Complication Assessment (DICA) classification, Combined Overview on Diverticular Assessment (CODA) score, and fecal calprotectin (FC)., Methods: An international, multicenter, prospective cohort study was conducted in 43 centers. A 10-point visual analog scale (VAS) was used to assess the severity of constipation and diarrhea. The association of constipation and diarrhea with DICA classification, CODA score, and basal FC was tested using non-parametric tests. Survival methods for censored observations were applied to test the association of constipation and diarrhea with the incidence of acute diverticulitis over a 3-year follow-up., Results: Of 871 patients with DD were included in the study. Of these, 208 (23.9%) and 199 (22.9%) reported a VAS score for constipation and diarrhea at least 3 at baseline, respectively. Higher constipation and diarrhea scores were associated with increasing DICA classification, CODA score and basal FC (P< 0.001). Constipation and diarrhea scores were independently associated with an increased hazard of developing acute diverticulitis (hazard ratio [HR]constipation = 1.15 per 1-VAS point increase, 95% confidence interval [CI], 1.04-1.27; P=0.004; and HRdiarrhea =1.14; 95% CI, 1.03-1.26; P=0.014, respectively)., Conclusions: In newly diagnosed patients with DD, higher endoscopic and combined scores of DD severity were associated with higher scores of constipation and diarrhea at baseline. Both constipation and diarrhea were independent prognostic factors of acute diverticulitis.

Published
2024
Full Text
View/download PDF

35. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.

Author

Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, and Papa A

Subjects
Humans, Adalimumab therapeutic use, Retrospective Studies, Treatment Outcome, Biosimilar Pharmaceuticals therapeutic use, Inflammatory Bowel Diseases drug therapy, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy
Abstract

Background: Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the originator. However, comparative data on the efficacy and safety of the various ADA biosimilars remains scarce.We compare the efficacy and safety of ADA biosimilars SB5, ABP501, GP2017, and MSB11022 in treating IBD outpatients in a real-life Italian setting., Methods: A retrospective analysis was performed on consecutive IBD outpatients with complete clinical, laboratory, and endoscopic data. Clinical activity was measured using the Mayo score in ulcerative colitis (UC) and the Harvey-Bradshaw Index in Crohn's disease (CD). The primary endpoints were the following: (1) induction of remission in patients new to biologics and patients new to ADA but previously exposed to other anti-tumor necrosis factor agents or other biologics; (2) maintenance of remission in patients switched from the ADA originator to an ADA biosimilar; and (3) safety of various biosimilars., Results: A total of 533 patients were enrolled according to the inclusion criteria: 162 patients with UC and 371 patients with CD. Clinical remission was obtained in 79.6% of patients new to biologics and 59.2% of patients new to ADA but not to other biologics; clinical remission was maintained in 81.0% of patients switched from the originator, and adverse events were recorded in 6.7% of patients. There was no significant difference between the 4 ADA biosimilars for each predetermined endpoint., Conclusions: Adalimumab biosimilars are effective and safe in IBD treatment, both in new patients and in patients switched from the ADA originator. No difference in efficacy and safety was found between ADA biosimilars., (© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results